ea0070aep579 | Pituitary and Neuroendocrinology | ECE2020
Otsuka Fumio
, Takahashi Yutaka
, Tahara Shigeyuki
, Ogawa Yoshihisa
, Højby Rasmussen Michael
, Takano Koji
Somapacitan is a long-acting, reversible albumin-binding growth hormone (GH) derivative. The objective of this trial was to evaluate the safety, efficacy and treatment satisfaction of onceweekly somapacitan versus daily GH (Norditropin) over 52 weeks in Japanese patients with adult GH deficiency (AGHD). This was a phase 3, multicentre, randomised, open-label, parallel-group, active-controlled trial (NCT03075644). Patients previously treated with GH were randomised 1:3 to daily...